

Appendix 8 (as supplied by the authors): Baseline characteristics of macrolide antibiotic (azithromycin, clarithromycin or erythromycin) users and non-macrolide antibiotic (amoxicillin, cefuroxime or levofloxacin) users pre- and post-match* (all 106 baseline characteristics)

Variable	Unmatched			Matched		
	Macrolide (n = 616,359)	Non-Macrolide (n = 705,132)	Standardized Difference†	Macrolide (n = 503,612)	Non-Macrolide (n = 503,612)	Standardized Difference†
Demographics						
Age, mean (SD), years	73.7 (7.1)	74.1 (7.3)	6%	73.9 (7.2)	74.0 (7.2)	2%
Women	359,895 (58.4)	389,520 (55.2)	6%	288,515 (57.3)	288,473 (57.3)	0%
Income quintile‡						
1 (low)	120,433 (19.5)	135,873 (19.3)	1%	99,340 (19.7)	100,535 (20.0)	1%
2	128,791 (20.9)	147,680 (20.9)	0%	106,101 (21.1)	106,738 (21.2)	0%
3 (middle)	121,353 (19.7)	139,156 (19.7)	0%	101,012 (20.1)	101,455 (20.1)	0%
4	120,224 (19.5)	138,126 (19.6)	0%	97,895 (19.4)	97,247 (19.3)	0%
5 (high)	123,398 (20.0)	141,829 (20.1)	0%	99,264 (19.7)	97,637 (19.4)	1%
Year of cohort entry						
2002	71,875 (11.7)	71,491 (10.1)	5%	56,548 (11.2)	56,434 (11.2)	0%
2003	89,014 (14.4)	86,440 (12.3)	6%	69,300 (13.8)	68,989 (13.7)	0%
2004	70,341 (11.4)	71,392 (10.1)	4%	55,248 (11.0)	55,193 (11.0)	0%
2005	63,839 (10.4)	66,701 (9.5)	3%	50,803 (10.1)	51,007 (10.1)	0%
2006	51,400 (8.3)	59,498 (8.4)	0%	42,229 (8.4)	42,502 (8.4)	0%
2007	46,988 (7.6)	55,608 (7.9)	1%	38,824 (7.7)	38,995 (7.7)	0%
2008	46,180 (7.5)	54,246 (7.7)	1%	37,802 (7.5)	37,898 (7.5)	0%
2009	41,919 (6.8)	53,244 (7.6)	3%	35,205 (7.0)	35,175 (7.0)	0%
2010	42,552 (6.9)	55,593 (7.9)	4%	35,973 (7.1)	35,860 (7.1)	0%
2011	41,502 (6.7)	58,617 (8.3)	6%	36,529 (7.3)	36,470 (7.2)	0%
2012	41,276 (6.7)	60,475 (8.6)	7%	37,075 (7.4)	37,011 (7.3)	0%
2013	9,473 (1.5)	11,827 (1.7)	1%	8,076 (1.6)	8,078 (1.6)	0%
Rural residence§	87,490 (14.2)	89,820 (12.7)	4%	68,952 (13.7)	67,861 (13.5)	1%
Long-term care	20,921 (3.4)	37,020 (5.3)	9%	20,538 (4.1)	23,129 (4.6)	3%
LHIN						
1	71,875 (11.7)	71,491 (10.1)	5%	56,548 (11.2)	56,434 (11.2)	0%
2	89,014 (14.4)	86,440 (12.3)	6%	69,300 (13.8)	68,989 (13.7)	0%
3	70,341 (11.4)	71,392 (10.1)	4%	55,248 (11.0)	55,193 (11.0)	0%
4	63,839 (10.4)	66,701 (9.5)	3%	50,803 (10.1)	51,007 (10.1)	0%
5	51,400 (8.3)	59,498 (8.4)	0%	42,229 (8.4)	42,502 (8.4)	0%
6	46,988 (7.6)	55,608 (7.9)	1%	38,824 (7.7)	38,995 (7.7)	0%
7	46,180 (7.5)	54,246 (7.7)	1%	37,802 (7.5)	37,898 (7.5)	0%
8	41,919 (6.8)	53,244 (7.6)	3%	35,205 (7.0)	35,175 (7.0)	0%
9	42,552 (6.9)	55,593 (7.9)	4%	35,973 (7.1)	35,860 (7.1)	0%
10	41,502 (6.7)	58,617 (8.3)	6%	36,529 (7.3)	36,470 (7.2)	0%
11	41,276 (6.7)	60,475 (8.6)	7%	37,075 (7.4)	37,011 (7.3)	0%
12	9,473 (1.5)	11,827 (1.7)	1%	8,076 (1.6)	8,078 (1.6)	0%
13	71,875 (11.7)	71,491 (10.1)	5%	56,548 (11.2)	56,434 (11.2)	0%
14	89,014 (14.4)	86,440 (12.3)	6%	69,300 (13.8)	68,989 (13.7)	0%
Prescribing physician¶						
General practitioner	474,660 (77.0)	398,920 (56.6)	44%	367,302 (72.9)	368,847 (73.2)	1%
Internist	2,797 (0.5)	2,967 (0.4)	1%	2,461 (0.5)	2,611 (0.5)	0%

Nephrologist	802 (0.1)	788 (0.1)	1%	749 (0.1)	626 (0.1)	1%
Cardiologist	856 (0.1)	1,146 (0.2)	1%	813 (0.2)	909 (0.2)	0%
Other	37,133 (6.0%)	38,396 (5.4)	2%	32,194 (6.4)	34,646 (6.9)	2%
Comorbidities**						
Dementia	46,958 (7.6)	68,671 (9.7)	8%	42,887 (8.5)	45,532 (9.0)	2%
Schizophrenia or other psychotic disorders	12,614 (2.0)	17,771 (2.5)	3%	11,363 (2.3)	11,985 (2.4)	1%
Bipolar disorder	9,964 (1.6)	12,986 (1.8)	2%	8,645 (1.7)	8,764 (1.7)	0%
Unipolar depression and/or anxiety disorder	46,254 (7.5)	53,089 (7.5)	0%	38,397 (7.6)	38,481 (7.6)	0%
Haemorrhagic stroke	1,056 (0.2)	1,556 (0.2)	1%	957 (0.2)	990 (0.2)	0%
Ischemic stroke	6,544 (1.1)	9,804 (1.4)	3%	6,005 (1.2)	6,366 (1.3)	1%
TIA	2,545 (0.4)	3,475 (0.5)	1%	2,263 (0.4)	2,363 (0.5)	0%
Chronic liver disease	19,210 (3.1)	23,094 (3.3)	1%	16,167 (3.2)	16,299 (3.2)	0%
Chronic kidney disease††	27,800 (4.5)	36,539 (5.2)	3%	25,543 (5.1)	25,543 (5.1)	0%
Congestive heart failure	61,351 (10.0)	77,802 (11.0)	4%	56,214 (11.2)	56,214 (11.2)	0%
Coronary artery disease‡‡	158,521 (25.7)	190,688 (27.0)	3%	138,038 (27.4)	138,038 (27.4)	0%
Angina	117,261 (19.0)	135,415 (19.2)	0%	99,400 (19.7)	99,463 (19.7)	0%
Peripheral vascular disease	8,365 (1.4)	10,267 (1.5)	1%	7,422 (1.5)	7,537 (1.5)	0%
Parkinson's disease	8,858 (1.4)	13,096 (1.9)	3%	7,995 (1.6)	8,289 (1.6)	0%
Chronic lung disease	177,653 (28.8)	167,962 (23.8)	11%	138,346 (27.5)	136,245 (27.1)	1%
Atrial fibrillation/flutter	25,513 (4.1)	39,678 (5.6)	7%	23,970 (4.8)	25,574 (5.1)	1%
Cancer§§	76,143 (12.4)	86,596 (12.3)	0%	62,477 (12.4)	62,302 (12.4)	0%
Alcoholism	3,578 (0.6)	4,757 (0.7)	1%	3,187 (0.6)	3,263 (0.6)	0%
Seizure	3,058 (0.5)	4,290 (0.6)	2%	2,772 (0.6)	2,936 (0.6)	0%
Acute kidney injury	6,238 (1.0)	9,090 (1.3)	3%	5,849 (1.2)	6,079 (1.2)	0%
Acute myocardial infarction	18,673 (3.0)	23,811 (3.4)	2%	16,863 (3.3)	16,947 (3.4)	0%
Pacemaker	23,606 (3.8)	31,405 (4.5)	3%	21,185 (4.2)	21,497 (4.3)	0%
Hospitalization with hyperkalemia	2,607 (0.4)	3,358 (0.5)	1%	2,374 (0.5)	2,422 (0.5)	0%
Hypotension	6,289 (1.0)	8,542 (1.2)	2%	5,661 (1.1)	5,838 (1.2)	0%
Prostatic hyperplasia	72,621 (11.8)	90,528 (12.8)	3%	61,284 (12.2)	61,487 (12.2)	0%
Prostatitis	28,193 (4.6)	33,028 (4.7)	1%	23,411 (4.6)	23,426 (4.7)	0%
Acute urinary retention	7,970 (1.3)	10,869 (1.5)	2%	7,068 (1.4)	7,248 (1.4)	0%
DVT/PE	942 (0.2)	1,611 (0.2)	2%	892 (0.2)	1,005 (0.2)	1%
Charlson comorbidity index						
0	394,182 (64.0)	441,541 (62.6)	3%	396,258 (78.7)	394,517 (78.3)	1%
1	151,182 (24.5)	173,421 (24.6)	0%	44,718 (8.9)	45,227 (9.0)	0%
2	36,695 (6.0)	44,093 (6.3)	1%	31,456 (6.2)	31,689 (6.3)	0%
≥ 3	34,300 (5.6)	46,077 (6.5)	4%	31,180 (6.2)	32,179 (6.4)	1%
Johns Hopkins Aggregated Diagnosis Groups						
0	14,708 (2.4)	18,706 (2.7)	2%	12,004 (2.4)	11,646 (2.3)	0%
1-2	107,191 (17.4)	129,336 (18.3)	2%	87,530 (17.4)	87,189 (17.3)	0%
3-5	256,541 (41.6)	289,615 (41.1)	1%	207,832 (41.3)	207,381 (41.2)	0%
≥ 6	237,919 (38.6)	267,475 (37.9)	1%	196,246 (39.0)	197,396 (39.2)	0%
Medication use¶¶						
Antiarrhythmic	8,265 (1.3)	13,318 (1.9)	4%	7,897 (1.6)	8,306 (1.6)	1%
Antipsychotic	15,803 (2.6)	24,798 (3.5)	6%	14,803 (2.9)	15,909 (3.2)	1%
Proton pump inhibitor	113,986 (18.5)	127,557 (18.1)	1%	94,018 (18.7)	94,081 (18.7)	0%
Antiemetic	3,353 (0.5)	4,417 (0.6)	1%	2,971 (0.6)	3,137 (0.6)	0%

Lithium	1,230 (0.2)	1,737 (0.2)	1%	1,071 (0.2)	1,079 (0.2)	0%
Antilipemic	221,688 (36.0)	272,129 (38.6)	5%	188,554 (37.4)	189,507 (37.6)	0%
Antihypertensive	378,579 (61.4)	441,513 (62.6)	2%	315,012 (62.6)	316,392 (62.8)	1%
Potassium sparing diuretic	7,394 (1.2)	7,828 (1.1)	1%	5,943 (1.2)	5,882 (1.2)	0%
H2RA	45,412 (7.4)	49,780 (7.1)	1%	37,562 (7.5)	38,034 (7.6)	0%
Prokinetic	12,338 (2.0)	14,799 (2.1)	1%	10,793 (2.1)	10,792 (2.1)	0%
QT-prolonging	79,216 (12.9)	96,628 (13.7)	3%	68,376 (13.6)	68,376 (13.6)	0%
Antidiabetic	86,160 (14.0)	107,168 (15.2)	3%	74,116 (14.7)	75,326 (15.0)	1%
Acetylsalicylic acid	45,102 (7.3)	50,932 (7.2)	0%	38,140 (7.6)	38,469 (7.6)	0%
Anticoagulant***	1,097 (0.2)	1,913 (0.3)	2%	1,053 (0.2)	1,116 (0.2)	0%
Antiplatelet	21,137 (3.4)	26,750 (3.8)	2%	18,705 (3.7)	18,835 (3.7)	0%
Tricyclic antidepressant	16,779 (2.7)	18,043 (2.6)	1%	13,898 (2.8)	13,639 (2.7)	0%
Opioid	144 (0.0)	152 (0.0)	0%	115 (0.0)	121 (0.0)	0%
Antimalarian	4,165 (0.7)	3,976 (0.6)	1%	3,218 (0.6)	3,126 (0.6)	0%
Antiviral	70 (0.0)	78 (0.0)	0%	59 (0.0)	57 (0.0)	0%
Antineoplastic	18,251 (3.0)	19,862 (2.8)	1%	14,617 (2.9)	14,760 (2.9)	0%
Benzodiazepine	95,661 (15.5)	106,325 (15.1)	1%	78,922 (15.7)	79,561 (15.8)	0%
NSAID†††	96,993 (15.7)	102,468 (14.5)	3%	77,699 (15.4)	77,092 (15.3)	0%
Cholinesterase inhibitor	0 (0.0)	0 (0.0)	0%	-	-	-
Anticonvulsant	12,039 (2.0)	17,052 (2.4)	3%	10,861 (2.2)	11,419 (2.3)	1%
ACE/ARB	244,089 (39.6)	286,273 (40.6)	2%	203,598 (40.4)	204,220 (40.6)	0%
Beta-adrenergic antagonist	143,479 (23.3)	175,820 (24.9)	4%	122,840 (24.4)	123,696 (24.6)	0%
Calcium channel blocker	137,188 (22.3)	162,728 (23.1)	2%	115,643 (23.0)	116,434 (23.1)	0%
Non-potassium sparing diuretic	140,191 (22.7)	164,702 (23.4)	1%	117,731 (23.4)	118,689 (23.6)	0%
Statin	206,154 (33.4)	253,885 (36.0)	5%	175,534 (34.9)	176,476 (35.0)	0%
Antiparkinson drug	7,655 (1.2)	11,610 (1.6)	3%	6,976 (1.4)	7,263 (1.4)	0%
Digoxin	16,465 (2.7)	27,748 (3.9)	7%	15,850 (3.1)	17,362 (3.4)	2%
Overactive bladder medication	11,989 (1.9)	15,337 (2.2)	2%	10,306 (2.0)	10,385 (2.1)	0%
Warfarin	28,511 (4.6)	52,322 (7.4)	12%	27,911 (5.5)	31,117 (6.2)	3%
Inhaler - acetylcholine	26,454 (4.3)	26,784 (3.8)	3%	21,534 (4.3)	21,606 (4.3)	0%
Inhaler - corticosteroid	38,465 (6.2)	32,138 (4.6)	7%	28,792 (5.7)	27,560 (5.5)	1%
Inhaler - beta-agonist	71,383 (11.6)	61,638 (8.7)	9%	54,089 (10.7)	52,530 (10.4)	1%
Smoking cessation aid	213 (0.0)	220 (0.0)	0%	162 (0.0)	164 (0.0)	0%
Health care use†††						
GP/FP visits	588,000 (95.4)	671,789 (95.3)	1%	480,748 (95.5)	481,050 (95.5)	0%
Specialist consultations						
Nephrologist consults	23,354 (3.8)	31,104 (4.4)	3%	20,866 (4.1)	21,237 (4.2)	0%
Cardiologist consults	192,925 (31.3)	233,623 (33.1)	4%	163,132 (32.4)	164,185 (32.6)	0%
Prior investigations and treatments						
Carotid ultrasound	23,718 (3.8)	27,395 (3.9)	0%	19,805 (3.9)	19,657 (3.9)	0%
Cardiac catheterization	7,618 (1.2)	10,102 (1.4)	2%	6,875 (1.4)	7,053 (1.4)	0%
Coronary angiogram	8,845 (1.4)	11,493 (1.6)	2%	7,944 (1.6)	8,096 (1.6)	0%
Echocardiography	76,276 (12.4)	95,002 (13.5)	3%	65,733 (13.1)	66,452 (13.2)	0%
EEG	2,452 (0.4)	3,074 (0.4)	1%	2,098 (0.4)	2,099 (0.4)	0%
Holter monitoring	27,888 (4.5)	35,025 (5.0)	2%	23,889 (4.7)	24,311 (4.8)	0%
Cardiac stress test	59,803 (9.7)	68,956 (9.8)	0%	49,842 (9.9)	49,678 (9.9)	0%

Coronary revascularization	4,282 (0.7)	5,866 (0.8)	2%	3,917 (0.8)	4,044 (0.8)	0%
Electrocardiography	270,574 (43.9)	319,725 (45.3)	3%	225,533 (44.8)	226,738 (45.0)	0%
Colorectal cancer screening	120,943 (19.6)	135,540 (19.2)	1%	96,970 (19.3)	96,028 (19.1)	0%
Cervical cancer screening	50,974 (8.3)	52,085 (7.4)	3%	39,122 (7.8)	38,535 (7.7)	0%
PSA test	11,272 (1.8)	16,987 (2.4)	4%	10,216 (2.0)	10,024 (2.0)	0%
Mammography	62,602 (10.2)	62,137 (8.8)	5%	48,148 (9.6)	47,222 (9.4)	1%
Influenza vaccination	330,636 (53.6)	372,220 (52.8)	2%	269,517 (53.5)	269,306 (53.5)	0%
Bone mineral density test	78,822 (12.8)	82,424 (11.7)	3%	61,728 (12.3)	60,823 (12.1)	1%
Hearing test	28,892 (4.7)	32,190 (4.6)	1%	23,566 (4.7)	23,393 (4.6)	0%
Cystoscopy	16,682 (2.7)	21,408 (3.0)	2%	14,405 (2.9)	14,577 (2.9)	0%
Transurethral resection of the prostate	1,314 (0.2)	1,869 (0.3)	1%	1,169 (0.2)	1,211 (0.2)	0%
CT of the head	36,303 (5.9)	47,676 (6.8)	4%	31,556 (6.3)	32,637 (6.5)	1%
CT of other areas	53,665 (8.7)	63,780 (9.0)	1%	45,195 (9.0)	45,595 (9.1)	0%
Chest x-ray	25,312 (4.1)	22,786 (3.2)	5%	19,484 (3.9)	19,263 (3.8)	0%
Pulmonary function test	50,909 (8.3)	51,816 (7.3)	3%	40,495 (8.0)	40,142 (8.0)	0%
At-home physician service	16,262 (2.6)	19,799 (2.8)	1%	14,109 (2.8)	14,329 (2.8)	0%
Urinalysis	9,521 (1.5)	34,249 (4.9)	19%	9,520 (1.9)	9,786 (1.9)	0%
Sputum	483 (0.1)	399 (0.1)	1%	367 (0.1)	356 (0.1)	0%
Kidney function§§§						
Baseline SCr concentration, median (IQR), µmol/L	78 (66-93)	79 (67-94)	4%	79 (67-93)	78 (66-93)	1%
eGFR, median (IQR), mL/min/1.73 m ²	74 (61-86)	74 (61-86)	2%	74 (61-86)	74 (61-86)	1%
eGFR						
≥ 60 mL/min/1.73 m ²	81,332 (13.2)	95,913 (13.6)	1%	66,755 (13.3)	66,942 (13.3)	0%
45-59 mL/min/1.73 m ²	16,125 (2.6)	19,597 (2.8)	1%	13,793 (2.7)	13,534 (2.7)	0%
30-44 mL/min/1.73 m ²	6,352 (1.0)	8,217 (1.2)	1%	5,630 (1.1)	5,637 (1.1)	0%
15-29 mL/min/1.73 m ²	1,735 (0.3)	2,478 (0.4)	1%	1,581 (0.3)	1,661 (0.3)	0%
< 15 mL/min/1.73 m ²	226 (0.0)	310 (0.0)	0%	217 (0.0)	202 (0.0)	0%
Urine dipstick protein¶¶¶						
Negative (≤ 0.3 g/L)	612 (0.1)	803 (0.1)	0%	533 (0.1)	508 (0.1)	0%
0.3 g/L - 1.0 g/L	8,734 (1.4)	10,935 (1.6)	1%	7,362 (1.5)	7,372 (1.5)	0%
1.0 g/L - 3.0 g/L	6,985 (1.1)	8,933 (1.3)	1%	5,926 (1.2)	6,148 (1.2)	0%
≥ 3.0 g/L	6,250 (1.0)	8,444 (1.2)	2%	5,517 (1.1)	5,711 (1.1)	0%

Abbreviations: ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blocker, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration, DVT/PE = deep vein thrombosis/pulmonary embolism, eGFR = estimated glomerular filtration rate, GP/FP = general practitioner/family practitioner, H2RA = Histamine H2 receptor antagonist, IQR = interquartile range, LHIN = Local Health Integration Network, NSAID = non-steroidal anti-inflammatory drug, SCr = serum creatinine, SD = standard deviation

*Data are presented as the number (percentage) of patients, unless otherwise reported.

†Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups divided by the pooled standard deviation; a value greater than 10% (0.1) is interpreted as a meaningful difference between the groups¹.

‡Income was categorized into fifths of average neighborhood income on the index date. Income was not available for 2,160 (0.4%) macrolide antibiotic users and 2,468 (0.4%) non-macrolide antibiotic users in the unmatched cohort. Missing values in the unmatched cohort were re-classified into income quintile 3 during matching.

§Rural residence was defined as a population < 10,000 people. Residential information was not available for 647 (0.1%) macrolide antibiotic users and 708 (0.1%) non-macrolide antibiotic users in the unmatched cohort. Missing values in the unmatched cohort were re-classified into the "No" category during matching.

||LHIN refers to health authorities responsible for regional administration of public healthcare services in Ontario. LHIN was not available for 619 (0.1%) macrolide antibiotic users and 684 (0.1%) non-macrolide antibiotic users in the unmatched cohort and 500 (0.1%) macrolide users and 480 (0.1%) non-macrolide antibiotic users in the matched cohort.

¶Prescriber information was not available for 100,111 (16.2%) macrolide antibiotic users and 262,915 (37.3%) non-macrolide antibiotic users in the unmatched cohort and 100,093 (19.9%) macrolide antibiotic users and 95,973 (19.1%) non-macrolide antibiotic users in the matched cohort.

**Comorbid conditions in the five years preceding the index date were considered.

††We identified chronic kidney disease using an algorithm of hospital diagnostic diagnosis codes validated for older adults in our region². The presence of codes in this algorithm is associated with a median eGFR of 38 mL/min per 1.73 m² (IQR 27 to 52 mL/min per 1.73 m²), whereas an absence of codes is associated with a median eGFR of 69 mL/min per 1.73 m² (IQR 56 to 82 mL/min per 1.73 m²).

‡‡Coronary artery disease included receipt of coronary artery bypass graft surgery and percutaneous coronary intervention.

§§Major cancers included esophagus, lung, bowel, liver, pancreas, breast, male/female reproductive organs, as well as leukemias and lymphomas.

|||Charlson comorbidity index^{3,4} was calculated using five years of hospitalization data. "No hospitalizations" received a score of 0.

¶¶Baseline medication use in the 120 days preceding the index date was considered.

***Excludes warfarin.

†††Excludes acetylsalicylic acid.

‡‡‡Chest x-ray, urinalysis and sputum were assessed in the seven days preceding the index date. All other health care use was assessed in the one year preceding the index date.

§§§Baseline serum creatinine measurements were taken in routine care a median of 131 days (IQR 59 to 227 days) and 126 days (IQR 57 to 224 days) prior to the index date for macrolide antibiotic users and non-macrolide antibiotic users, respectively, in the unmatched cohort and 129 days (IQR 59 to 225 days) and 127 days (IQR 58 to 224 days) prior to the index date for macrolide antibiotic users and non-macrolide antibiotic users, respectively, in the matched cohort.

||||eGFR was calculated using the CKD-EPI equation⁵: $141 \times \min([\text{serum creatinine concentration in } \mu\text{mol/L}/88.4]/\kappa, 1)^\alpha \times \max([\text{serum creatinine concentration in } \mu\text{mol/L}/88.4]/\kappa, 1)^{-1.209} \times 0.993^{\text{Age}} \times 1.018$ [if female] $\times 1.159$ [if African-American]; $\kappa=0.7$ if female and 0.9 if male; $\alpha=-0.329$ if female and -0.411 if male; min=the minimum of serum creatinine concentration/ κ or 1; max=the maximum of serum creatinine concentration/ κ or 1. Information on race was not available in our data sources and all patients were assumed not to be of African-Canadian race; African-Canadians represented less than 5% of the population of Ontario in 2006⁶.

¶¶¶Urine dipstick protein measurements were available for 22,581 (3.7%) macrolide antibiotic users and 29,115 (4.1%) non-macrolide antibiotic users in the unmatched cohort and 19,338 (3.8%) macrolide antibiotic users and 19,739 (3.9%) non-macrolide antibiotic users in the matched cohort.

References

1. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. *Commun Stat Simul Comput* 2009;38:1228-34.
2. Fleet JL, Dixon SN, Shariff SZ, et al. Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. *BMC Nephrol* 2013;14:81.
3. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-83.
4. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;43:1130-9.
5. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604-12.
6. Statistics Canada. Ethnic origin and visible minorities. 2006.